|
IM-MV 19-016_000
|
Erasmus MC
|
Gene therapy clinical development program (CDP) comprising clinical trials using the advanced therapy medicinal product (ATMP) SPK-3006, a recombinant adeno-associated viral (AAV) vector with a bioengineered capsid and a codon-optimized expression cassette encoding a secretable human acid alpha glucosidase (GAA) gene for gene transfer in individuals with Pompe disease
|
18-12-2019
|
Vergunning verleend
|
|
IM-MV 19-019_000
|
Erasmus MC
|
Testing the safety and efficacy of JCAR017 in patients with aggressive B cell malignancies
|
13-12-2019
|
Vergunning verleend
|
|
IM-MV 19-020_000
|
Stichting Katholieke Universiteit
|
A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-seropositive Donors (D+)
|
09-01-2020
|
Vergunning verleend
|
|
IM-MV 19-021_000
|
Erasmus MC
|
Clinical Trials to Assess the Safety and/or Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells (GSK3377794), alone or in combination with other agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 Participants with NY-ESO-1 and/or LAGE-1a Positive Cancers
|
13-12-2019
|
Vergunning verleend
|
|
IM-MV 19-023_000
|
UMCG
|
Clinical Trials to Assess the Safety and/or Antitumor Activity of Genetically Engineered NY-ESO-1-specific (c259) T cells (GSK3377794), alone or in combination with other agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 Participants with NY-ESO and/or LAGE-1a Positive Cancers
|
18-12-2019
|
Vergunning verleend
|
